Gefitinib treatment can also induce changes in the levels of immune checkpoint protein PD-L1 in sEVs derived from NSCLC cell lines, which were resistant to different drugs, including gefitinib, erlotinib and crizotinib. This evidence concerns the gene CD274 and non-small cell lung carcinoma.